Skip to main content
SpringerLink
Log in

Ezetimibe: profile report

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Darkes MJM, Poole RM, Goa KL. Ezetimibe. Am J Cardiovasc Drugs 2003; 3(1): 67–78

    Article  PubMed  CAS  Google Scholar 

  2. Bays H. Ezetimibe: a viewpoint by Harold Bays. Am J Cardiovasc Drugs 2003; 3(1): 77

    Article  Google Scholar 

  3. Wierzbicki AS. Ezetimibe: a viewpoint by Anthony S. Wierzbicki. Am J Cardiovasc Drugs 2003; 3(1): 77

    Article  Google Scholar 

  4. Libby P. Atherosclerosis: the new view. Sci Am 2002; May: 29–37

  5. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321: 1322–5

    Article  PubMed  CAS  Google Scholar 

  6. van Heek M, Farley C, Compton DS, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001; 134(2): 409–17

    Article  PubMed  Google Scholar 

  7. Sudhop T, Von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 2002; 62(16): 2333–47

    Article  PubMed  CAS  Google Scholar 

  8. Davis HR, Compton DS, Hoos L, et al. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits entertocyte cholesterol uptake and absorption [abstract no. P3500]. Eur Heart J 2000 Aug; 21 (Abstr. Suppl.): 636

  9. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002 Nov 15; 90: 1092–7

    Article  PubMed  CAS  Google Scholar 

  10. Knopp RH, Gitter H, Truitt T, et al. Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trial [abstract no. W6.2]. Atherosclerosis Suppl 2001 May; 2(2): 38

    Article  Google Scholar 

  11. Davidson M, McGarry T, Bettis R, et al. Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002 Dec 18; 40(12): 2125–34

    Article  PubMed  CAS  Google Scholar 

  12. Lipka L, Kerzner B, Corbelli J, et al. Results of ezetimibe co-administered with lovastatin in 548 patients with primary hypercholesterolemia [abstract]. J Am Coll Cardiol 2002 May 1; 39 Suppl.B:430B

  13. Melani L, Mills R, Hassman D, et al. Ezetimibe co-administered with pravastatin in 538 patients with primary hypercholesterolemia [abstract]. J Am Coll Cardiol 2002 May 1; 39 Suppl. B: 134–135 (plus poster presented at the XIV World Congress of Cardiology, 2002 May, Sydney)

  14. Ballantyne C, Houri J, Notarbartolo A, et al. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia [abstract]. J Am Coll Cardiol 2002 May 1; 39 Suppl. B: 135–136 (plus poster presented at the XIV World Congress of Cardiology, 2002 May, Sydney)

  15. Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardio 2002; 90 (15 Nov): 1084–91

    Article  Google Scholar 

  16. Gagné C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Ezetimibe Study Group. Circulation 2002; 105(21): 2469–75

    Article  PubMed  Google Scholar 

  17. Salen G, von Bergmann K, Kwiterovich P, et al. Ezetimbe is an effective treatment for homozygous sitosterolemia [abstract no. 929]. American Heart Association 75th Scientific Sessions 2002 Nov 17–20, Orlando, Florida

  18. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001 Aug; 23(8): 1209–30

    Article  PubMed  CAS  Google Scholar 

  19. Bays HE. Ezetimibe. Expert Opin Investig Drugs 2002; 11(11): 1587–604

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA

    Harold Bays

  2. Department of Chemical Pathology, St Thomas’ Hospital, London, England

    Anthony S. Wierzbicki

Authors
  1. Harold Bays
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony S. Wierzbicki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bays, H., Wierzbicki, A.S. Ezetimibe: profile report. Drugs Ther. Perspect 19, 5–6 (2003). https://doi.org/10.2165/00042310-200319060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319060-00002

Keywords

Search

Navigation